ACIU

AC Immune SA (ACIU)

About AC Immune SA (ACIU)

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Details

Daily high
$3.34
Daily low
$3.28
Price at open
$3.30
52 Week High
$5.14
52 Week Low
$2.20
Market cap
330.9M
Dividend yield
0.00%
Volume
44,969
Avg. volume
97,960
P/E ratio
-4.62

AC Immune SA News

Details

Daily high
$3.34
Daily low
$3.28
Price at open
$3.30
52 Week High
$5.14
52 Week Low
$2.20
Market cap
330.9M
Dividend yield
0.00%
Volume
44,969
Avg. volume
97,960
P/E ratio
-4.62